1585 South Perry Street
United States - Map
Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The companys research and development activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. The company, through its license agreement with Washington University in St. Louis, develops, markets, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for cattle, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.
|Mr. Stephen T. Lundy ,
Chief Exec. Officer, Pres and Director
|Mr. Jeffrey G. McGonegal ,
Chief Financial Officer, Principal Accounting Officer and Corp. Sec.
|Mr. Donald R. Hurd ,
Chief Commercial Officer and Sr. VP
|Dr. Mark A. Colgin Ph.D.,
Chief Scientific Officer
|Mr. Gregory S. Pusey ,
VP of Investor Relations
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|